|
業務類別
|
Biotechnology |
|
業務概覽
|
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs. |
| 公司地址
| 345 Park Avenue South, Floor 6, New York, NY, USA, 10010 |
| 電話號碼
| +1 212 547-9879 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.lexeotx.com |
| 員工數量
| 59 |
| Mr. Narinder P. Bhalla, M.D. |
Chief Medical Officer |
-- |
27/01/2026 |
| Mr. Louis Tamayo |
Chief Financial Officer and Principal Accounting Officer |
美元 181.82K |
30/04/2026 |
| Mr. Jose Manuel Otero, PhD |
Chief Operating Officer |
-- |
27/01/2026 |
| Mr. Richard Nolan Townsend |
Director and Chief Executive Officer |
美元 632.70K |
30/04/2026 |
|
|
| Mr. Tim Van Hauwermeiren, M. Sc. |
Independent Director |
30/04/2026 |
| Mr. Tolga Tanguler |
Independent Director |
30/04/2026 |
| Dr. Laura Sepp-Lorenzino, PhD |
Independent Director |
30/04/2026 |
| Ms. Paula H.J. Cholmondeley |
Independent Director |
30/04/2026 |
| Dr. Steven Altschuler, M.D. |
Chairman of the Board |
30/04/2026 |
| Ms. Mette Kirstine Agger |
Independent Director |
30/04/2026 |
| Mr. Reinaldo M. Diaz |
Independent Director |
30/04/2026 |
| Dr. Brenda Cooperstone, M.D. |
Independent Director |
30/04/2026 |
| Mr. Richard Nolan Townsend |
Director and Chief Executive Officer |
30/04/2026 |
|
|
|
|
